BENNETT C FRANK

Bennett C. Frank, Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals (IONS), has been a consistent seller of company stock over the past year, with no open-market purchases recorded. Across 45 total Form 4 filings, his sales total approximately $20.5 million, while his only acquisitions—worth roughly $40,900—came from option exercises and equity grants, which are compensation events rather than discretionary buys. The pattern is unambiguous: every discretionary transaction in the filing history is a sale, and the recent activity shows no shift toward accumulation. The most concentrated selling occurred in early 2026. On March 3, Frank executed three open-market sales totaling about $6.7 million, paired with option exercises valued at roughly $3.5 million—a classic exercise-and-sell structure that liquidates shares rather than retaining them. Similarly, on February 2, he sold approximately $7.1 million across three separate transactions while exercising options worth about $3.5 million. Smaller sales punctuated the period: $1.28 million on July 7, 2026, $1.37 million on February 2, and $488,140 on January 30, among others. The most recent filings, dated July 7, 2026, show two sales totaling roughly $1.74 million, continuing the trend. The data reveals no buying conviction whatsoever. Frank’s sales are routine and substantial, often clustered around option exercise dates, which suggests a systematic approach to monetizing equity compensation rather than a reaction to specific price movements. His last open-market purchase is absent from the record entirely, and the 12 most recent trades are all sales or mechanical events (option exercises, tax withholdings, or grants). For investors tracking insider sentiment at Ionis, the signal is one-directional: Frank has been a net seller in every meaningful window over the past year, with total sales exceeding his compensation-related acquisitions by a factor of roughly 500.